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ABSTRACT 
 
Colorectal cancer (CRC) is the fourth most frequent type of cancer in both sexes 
worldwide. Most of the CRC are sporadic, but approximately 10% of the cases are 
hereditary. Lynch syndrome (LS) is the most common hereditary syndrome that 
predisposes patients to CRC, corresponding to 2-5% of all CRCs. It is described as an 
autosomal dominant disease caused by germline mutations in the DNA repair genes - 
Mismatch Repair (MMR) genes. These include MLH1, MSH2, MSH6 and PMS2, and 
about 90% of the mutations described in this syndrome occur in MLH1 or MSH2. There 
are cases described in the literature with clinical criteria for LS without germline mutation 
in MMR genes, which have “constitutional epimutations” or simply “'epimutations” in the 
MLH1 or in the MSH2 genes. This phenomenon consists in transcriptional silencing of the 
promoter of these genes by epigenetic mechanisms rather than by genetic mutations that 
directly affect the sequence of the gene. 
In a series of 38 patients from families who meet clinical criteria for LS, with loss of 
MLH1 expression in the tumor and with no germline mutations in the MLH1, we screened 
for constitutional methylation of the MLH1 gene promoter using methylation-specific 
multiplex ligation-dependent probe amplification (MS-MLPA). We found four (4/38; 10.5%) 
patients with constitutional methylation in the MLH1 gene promoter in mosaicism. RNA 
studies demonstrated a decreased MLH1 expression in the cases with constitutional 
methylation when compared with controls, and in two cases (heterozygous for a coding 
polymorphism) we could demonstrate that this reduction in expression was monoallelic. 
These results indicate that the constitutional MLH1 promoter methylation directly 
correlates with their reduction of expression. All tumors of the patients harboring 
constitutional methylation were microsatellite instability-high (MSI-H) and did not present 
the p.Val600Glu BRAF mutation. In addition, we were able to study three relatives of one 
of the probands (parents and sister). Constitutional methylation was not detected in any of 
the three family members, suggesting that the methylation arose de novo in this proband. 
Additional studies will be necessary for a correct classification of the origin of these 
epimutations. This classification will allow the identification of the risk for relatives to 
inherit the methylation and develop tumors associated with LS, thus allowing adapting 
screening and/or the prophylactic measures according to risk.  
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RESUMO 
 
O cancro colorretal (CCR) é a quarta neoplasia mais frequente em ambos os sexos 
em todo o mundo. A grande maioria dos CCRs são esporádicos, no entanto cerca de 
10% dos casos são hereditários. A síndrome de Lynch é a forma mais comum de CCR 
hereditário, correspondendo a 2-5% de todas as neoplasias colorretais. É descrita como 
uma doença autossómica dominante, causada por mutações germinativas nos genes de 
reparação do DNA - genes Mismatch Repair (MMR). Estes incluem os genes MLH1, 
MSH2, MSH6 e PMS2, e cerca de 90% das mutações descritas nesta síndrome ocorrem 
no MLH1 ou no MSH2. Existem casos descritos na literatura com critérios clínicos para 
síndrome de Lynch, sem mutação germinativa identificada nos genes MMR, que 
apresentam ''epimutações constitucionais'', ou simplesmente ''epimutações'' nos genes 
MLH1 ou MSH2. Estas consistem no silenciamento transcripcional do promotor destes 
genes por mecanismos epigenéticos, e não por mutações genéticas que afetam 
diretamente a sequência do próprio gene.  
Numa série de 38 pacientes pertencentes a famílias que cumprem critérios clínicos 
de síndrome de Lynch, com perda de expressão de MLH1 no tumor e sem mutações 
germinativas no MLH1, foi pesquisada metilação constitucional do promotor do gene 
MLH1, através da técnica de methylation-specific multiplex ligation-dependent probe 
amplification (MS-MLPA). Foram encontrados quatro (4/38; 10,5%) pacientes com 
metilação constitucional no gene MLH1 em mosaicismo. Estudos de RNA demonstraram 
redução da expressão do gene MLH1 nos casos com metilação constitucional quando 
comparados com controlos, e em dois casos (heterozigóticos para um polimorfismo 
codificante) foi possível demonstrar que essa redução de expressão era monoalélica. 
Estes resultados indicam que a metilação constitucional do promotor do MLH1 está 
correlacionada com a redução de expressão desse mesmo gene. Observamos que todos 
os tumores dos pacientes positivos para a metilação constitucional apresentavam alta 
instabilidade de microssatélites e não apresentavam a mutação p.Val600Glu do gene 
BRAF. Adicionalmente, foi possível estudar três familiares de um dos casos índice (pais e 
irmã). Não foi detetada metilação constitucional em nenhum dos três familiares, o que 
sugere que a metilação neste paciente surgiu de novo. Estudos adicionais serão 
necessários para uma correta classificação da origem destas epimutações. Esta 
classificação permitirá identificar o risco dos familiares herdarem a metilação e de 
desenvolverem tumores associados com a síndrome de Lynch, permitindo, assim, 
adoptar medidas de rastreio e/ou profilaxia adequadas ao risco.
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I. INTRODUCTION  
 
1. Overview of colorectal cancer 
Colorectal cancer (CRC) is a complex disease with a heterogeneous etiology, 
caused by a combination of numerous factors with environmental, genetic and 
epigenetic origins (Gryfe, 2009). It is characterized by an accumulation of genetic and 
epigenetic alterations leading to an invasive state, and usually occurs in one of three 
patterns: inherited, familial or sporadic (Berg and Søreide, 2011; Markowitz and 
Bertagnolli, 2009; Worthley et al., 2007). Inherited forms are responsible for about 5-
10% of all CRCs and are related to recognized hereditary conditions (Gryfe, 2009).  
 
2. Colorectal cancer epidemiology 
Currently, cancer is the leading cause of death in economically developed 
countries and the second leading cause of death in developing countries. CRC is 
increasing in economically developing countries as a result of population aging and 
growth, adoption of cancer-associated lifestyle choices, such as smoking, physical 
inactivity, and type of diet (Jemal et al., 2011). 
Considering both sexes, CRC was the fourth most common cancer in the world, 
accounting for 9.7% (1,360,602 cases) of all new cancer cases diagnosed in 2012, 
with an estimated age-standardized rate (ASR) incidence of 17.2/100,000 (Ferlay et 
al., 2013). CRC represents the fourth leading cause of cancer mortality with 8.5% 
(693,933 deaths) estimated worldwide, with an estimated ASR mortality of 8.4/100,000 
(Ferlay et al., 2013). More specifically, CRC is the third most incident cancer in men, 
with an estimated ASR incidence of 20.6/100,000 (746,000 cases, 10.0% of the total) 
and the second in women, with an estimated ASR incidence of 14.3/100,000 (614,000 
cases, 9.2% of the total) worldwide (figure 1) (Ferlay et al., 2013). CRC represents the 
fourth most common cause of death from cancer in men and the third in women, with 
an estimated ASR mortality of 10.0/100,000 and 6.9/100,000, respectively (Ferlay et 
al., 2013). Almost 55% of the cases occur in more developed regions. There is wide 
geographical variation in incidence across the world and the geographical patterns are 
very similar in men and women with incidence rates varying ten-fold in both sexes 
worldwide (figure 1) (Ferlay et al., 2013).  
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In 2012, CRC was the third most common malignancy in Europe in both sexes 
(excluding non-melanoma skin cancers), with 13.1% (447,136 newly diagnosed cases), 
with an estimated ASR incidence of 29.5/100,000 of all new cancer cases (Ferlay et al., 
2013). In Europe, CRC is slightly more incident in men than in women. In women it is the 
second most incident cancer, with an estimated ASR incidence of 23.6/100,000, and the 
third most common in men with an estimated ASR incidence of 37.3/100,000 (Ferlay et 
al., 2013). The main difference is that, in Europe, CRC is considered the second cause of 
cancer-related death, with an estimated ASR mortality of 12.5/100,000 in both sexes 
(figure 2) (Ferlay et al., 2013; Siegel et al., 2013).  
In Portugal, differences in incidence and mortality rates of this disease have been 
changing over the past few years. These rates have decrease due to screening, 
improvement in diagnosis and treatment, and, above all, by adopting healthier lifestyles 
(Jemal et al., 2011; Siegel et al., 2014). In 2012, it was the third highest incident 
malignancy, corresponding to 14.5% (7,129 new cases) with an estimated ASR incidence 
of 31.7/100,000 diagnosed in both sexes, after breast cancer in women and prostate in 
men. It was also the leading cause of death by cancer, which accounts for 15.7% (3,797 
deaths) of all cancer deaths, with an estimated ASR mortality of 13.6/100,000 in both 
sexes (figure 3) (Ferlay et al., 2013).  
 
 
Figure 1 - Estimated CRC incidence and mortality worldwide in 2012 for both sexes, all 
ages (Ferlay et al., 2013). 
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Figure 3 - Estimated age-standardized incidence and mortality rates of CRC in both sexes, 
in Portugal, all ages. ASR, age-standardized rates (Ferlay et al., 2013). 
 
 
 
 
V 
 
 
 
 
 
 
Figure 2 - Estimated age-standardized incidence and mortality rates of CRC for A) women 
and B) men in Europe, all ages. ASR, age-standardized rates (Ferlay et al., 2013). 
 
 
 
 
 
3. Etiology and risk factors 
The etiologic risk factors can be divided into environmental and genetic factors. 
Theoretically, environmental factors can be prevented and/or changed by the individual 
whereas the genetic factors are not under such control. Multiple dietary and lifestyle 
A) 
 
a) 
B) 
 
a) 
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factors are known to be related to an increased risk of developing CRC (Theodoratou et 
al., 2014). 
Several epidemiological studies have suggested that diet, physical inactivity, 
obesity, tobacco use, alcohol consumption, diabetes and the presence of inflammatory 
bowel diseases play an important role in the etiology of the disease (Huxley et al., 2009). 
In fact, it was suggested that nearly 66-77% of CRC might be preventable by an 
appropriate combination of diet, physical activity and a healthy lifestyle (Giovannucci, 
2002; Platz et al., 2000). High intake of animal fat may increase the risk of CRC, although 
previous studies have possibly overemphasized the risk. Other dietary components of 
etiological importance include vegetables, fibre and vitamin C (all of which probably lower 
the risk), whereas high alcohol consumption appears to increase it. The World Cancer 
Research Fund (WCRF), in combination with the American Institute for Cancer Research 
(AICR), in 2007, released the second expert report that summarizes the current scientific 
evidence on diet and nutrition, where it is estimated that these are responsible for about 
30-50% of the worldwide incidence of CRC. Diet and nutrient factors are widely believed 
to act as pro- and anti-tumor risk modifiers across the entire multistep process of CRC 
tumorigenesis, which includes tumor initiation, promotion, and progression (Vargas and 
Thompson, 2012). Furthermore, a number of reports have suggested that regular use of 
aspirin and/or non-steroidal anti-inflammatory drugs (NSAIDs) may be protective (Bosetti 
et al., 2012).  
Age and gender are also risk factors, since increasing age is associated with 
advanced neoplasia, and CRC incidence rates are lower in women than in men, with a 
particularly striking discrepancy between pre-menopausal women and age-matched men 
(Purim et al., 2013; Stegeman et al., 2013). The likelihood of diagnosis of CRC increases 
progressively (90%) in people aged 50 or older (Haggar and Boushey, 2009).  
Another important risk factor is family history (Stegeman et al., 2013). Up to 20% of 
people who develop CRC have other family members who have been affected by this 
disease (Giardiello et al., 2014). Individuals with history of CRC or adenomatous polyps in 
one or more first-degree relatives are at an increased risk. This risk is higher in people 
with a stronger family history, such as history of CRC or adenomatous polyps in any first-
degree relative younger than age 60; or history of CRC or adenomatous polyps in two or 
more first-degree relatives at any age. The reasons for the increased risk are not clear, 
but it is likely due to inherited mutations, shared environmental factors, or some 
combination of both (Dunlop et al., 2013). Approximately 5-10% of CRCs are a 
consequence of recognized hereditary conditions (Jasperson et al., 2010). Lynch 
syndrome (LS) and familial adenomatous polyposis (FAP) are the most common 
hereditary syndromes that predisposes patients to CRC (Hughes and Huang, 2011).  
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4. Anatomy and functionality of the large intestine 
The colon and rectum are portions of the digestive system, also called 
gastrointestinal system. Cancer develops less commonly in the small intestine than in the 
colon or in the rectum. The small intestine joins the large intestine in the lower right 
abdomen. The leading function of colon is to absorb water and mineral nutrients from the 
food matter (Tortora and Derrickson, 2012). The large intestine presents 1.5m long and 
6.5cm in diameter. The first portion, the cecum, forms a blind-ended pouch from which 
extends the appendix. The colon is divided into ascending, transverse, descending, and 
sigmoid portions. The ascending colon lies retroperitoneally, lacks a mesentery and it is 
continuous with the transverse colon at the hepatic (right) flexure of colon near the right 
inferior margin of the liver. The transverse colon has its own mesentery, the transverse 
mesocolon and it becomes continuous with the descending colon at the splenic (left) 
flexure. The terminal portion of the descending colon is S-shaped, forming the sigmoid 
colon, which empties into a relatively straight segment of the large intestine, the rectum, 
which ends at the anus (figure 4) (Widmaier, 2011). The ascending and transverse 
sections are collectively referred to as the proximal colon, while the descending and 
sigmoid colon are referred to as the distal colon (Tortora and Derrickson, 2012). Relatively 
to the anatomy of the rectum is usually divided into three portions: the lower rectum, the 
midrectum, and the upper rectum. The determination of the boundary between rectum and 
sigmoid colon is important in defining adjuvant therapy (DeVita et al., 2011). 
 
 
Figure 4 - Anatomy of the large intestine. Anterior view of large intestine showing major 
regions: Cecum, ascending colon, transverse colon, descending colon, sigmoid and rectum 
(adapted from Tortora and Derrickson, 2012). 
 
 
Figure 2 - Anatomy of the large Intestine. Anterior view of large intestine showing major 
regions: Cecum, ascending colon, transverse colon, descending colon, sigmoid and 
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5. Diagnosis and staging of colorectal cancer 
5.1. Screening and diagnosis 
Many symptoms of CRC have been described, with the main ones being rectal 
bleeding, diarrhea, constipation, loss of weight, cramping, abdominal pain, anemia, 
decreased appetite and weakness, and, in particular, obstructive symptoms (DeVita et al., 
2011; Labianca et al., 2013). Colorectal cancer diagnosis can be difficult because most of 
these symptoms are non-specific (Cappell, 2008). 
There is no test available for use in primary care that has sufficient discrimination to 
provide the basis for referral decisions, although primary care investigation sometimes 
includes fecal occult blood testing and estimation of hemoglobin (Astin et al., 2011). For 
example, Carcinoembryonic Antigen (CEA) is a tumor marker often elevated in CRC, but it 
is insufficiently specific to be a reliable indicator of the disease (He and Efron, 2011). Use 
of recommended CRC screening tests can both detect earlier or prevent CRC by 
promoting the removal of precancerous polyps (Bujanda et al., 2012; Cunningham et al., 
2010; Winawer et al., 2006). Recommended strategies for CRC screening fall into two 
broad categories: 1) stool DNA tests (sDNA): e.g. fecal occult blood test (FOBT), fecal 
immunochemical test (FIT) and fecal DNA testing; and 2) structural examinations: which 
comprises flexible sigmoidoscopy (FSIG), colonoscopy (CSPY), double-contrast barium 
enema (DCBE) and computed tomographic colonography (CTC) (Bujanda et al., 2012; 
Levin et al., 2008). Regarding the structural examinations, endoscopy methods can detect 
abnormalities and remove them in one procedure. The two main endoscopy procedures 
are FSIG and CSPY. With FSIG only approximately one-half of the colorectum can be 
examined, whereas CSPY generally visualizes the entire colorectum (Bujanda et al., 
2012; Hassan et al., 2005). According to the literature, there are specific guidelines 
described for CRC screening for individuals at average risk. Colonoscopy is also the most 
appropriate and sensitive test for CRC diagnosis. To evaluate the presence and extent of 
metastases, particularly in the liver, a physical examination combined with chest x-Ray, 
liver function tests, CEA level, computed tomography (CT) combined with 
Fluorodeoxyglucose-positron emission tomography (FDG-PET) or magnetic resonance 
imaging (MRI) are, currently, the best options (Heitman et al., 2010; Townsend, 2007; van 
Cutsem et al., 2010). 
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5.2. Histopathology and staging  
The type of colorectal tumor describes the cells from which the tumor arises. 
Typically, they may be divided into epithelial and non-epithelial. The first group 
encompasses the adenomas, carcinomas and carcinoid tumors, whilst the second group 
includes the malignant lymphomas and gastrointestinal stromal tumors (GISTs) (Hamilton 
and Aaltonen, 2000). 
Colorectal cancers can be classified as well differentiated, moderately differentiated, 
or poorly differentiated based on the degree of preservation of normal glandular 
architecture and cytologic features (Cappell, 2008). Approximately 20% of CRCs are 
poorly differentiated and they confer a poor prognosis (Hassan et al., 2005). Most 
colorectal carcinomas are gland-forming with variations in size and conformation of the 
glandular structures, and may be divided into several types according to those (table 1) 
(Hamilton and Aaltonen, 2000; Quirke et al., 2011).  
Adenocarcinoma is the most common type of colorectal carcinoma (nearly 85%) and 
10-15% are commonly diagnosed as mucinous adenocarcinoma (Lanza et al., 2011). 
Mucinous cancers are defined histologically by the presence of abundant extracellular 
mucin, with more than 50% of the tumor mass being mucinous (Marzouk and Schofield, 
2011). Other tumor types (signet-ring cell, small cell, squamous cell, medullary carcinoma 
and undifferentiated carcinomas) present a much lower incidence (Lanza et al., 2011). 
Approximately 20-25% of CRC patients initially presents metastases (Lanza et al., 
2011).  CRC metastasizes firstly to the liver because of the venous drainage of the colon 
via the portal system (Poston et al., 2008). Other sites, including the lungs, peritoneum, 
pelvis, and adrenals, typically become involved only after hepatic or lymphatic metastases 
occur. Rectal cancers, which are below the peritoneal reflection, lack a serosa and, 
therefore, penetrate firstly into adjacent pelvic structures (Hamilton and Aaltonen, 2000; 
Hugen et al., 2014). 
Pathologic tumor staging assessment in CRC remains a crucial step for prognostic 
evaluation and treatment decision. There are several staging systems. The Astler-Coller, 
the Duke’s, and the Tumor, Node and Metastases (TNM) system, being the latter the most 
commonly used, and the recommended by the American Joint Committee on Cancer 
(AJCC) (Centelles, 2012; Shia et al., 2012). Specifically, this staging describes the mural 
depth of the primary tumor (T), the presence of local lymph node metastases (N), and the 
presence of distant metastases (M) (table 1).  
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Table 1 - Overview of the AJCC TNM cancer staging system for colorectal carcinomas 
(adapted from Shia et al., 2012). 
  
TNM- Tumor, Node and Metastases. 
 
 
 
  The three letters T, N and M are combined with numbers in order to indicate 
increasing severity and progression of the disease (Edge and Compton, 2010). After 
combining the information of each letter, the stage can be assessed in a process called 
stage grouping, in which the stage is expressed in Roman numerals from I to IV (table 2) 
(Centelles, 2012). 
 
 
  
 Primary tumor (T) 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades muscularis propria into pericolorectal tissues 
T4a Tumor penetrates to the surface of the visceral peritoneum 
T4b Tumor directly invades or is adherent to other organs or structures 
 Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c 
Tumor deposit(s) in the subserosa, mesentery, or non-peritonealized pericolic or 
perirectal tissues without regional nodal metastasis 
N2 Metastasis in 4 or more regional lymph nodes 
N2a Metastasis in 4-6 or more regional lymph nodes 
N2b Metastasis in 7 or more regional lymph nodes 
 Distant metastasis (M) 
M0 No distant metastasis (no pathologic M0; use clinical M to complete stage group) 
M1 Distant metastasis 
M1a Metastasis confined to 1 organ or site (eg liver, lung, ovary, non-regional node) 
M1b Metastases in more than 1 organ/site or the peritoneum 
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Table 2 - Staging groups for CRC, according to AJCC guidelines (adapted from Centelles, 
2012). 
 
    AJCC, American Joint Committee on Cancer; CRC, Colorectal Cancer. 
 
6. Prognosis and treatment  
The prognosis of CRC is clearly related to the degree of tumor invasion through the 
bowel wall and the presence or absence of nodal involvement. Important parameters 
include grading, lymphatic, venous or perineural invasion, lymphoid inflammatory 
response, and involvement of resection margins. Many other possibly prognostic factors, 
such as proliferation index and aneuploidy, are under evaluation for their single or 
combined value in high risk conditions. Bowel obstruction and perforation are clinical 
indicators of a poor prognosis. Elevated pretreatment serum levels of CEA and/or 
carbohydrate antigen 19-9 (CA19-9) have a negative prognostic significance (Labianca et 
al., 2010). The most widely studied marker CEA may be useful in the preoperative staging 
and postoperative follow-up of patients with large bowel cancer, but has a low predictive 
value for diagnosis in asymptomatic patients due to its relatively low sensitivity and 
specificity (Schmoll et al., 2012).  
Relatively to treatment, surgery is the most common treatment for locoregional colon 
and rectal carcinoma (Siegel et al., 2013). According to the Nacional Cancer 
Comprehensive Network (NCCN), in colon cancer adjuvant chemotherapy is administered 
to reduce the risk of recurrence, in particular 5-fluorouracil (5-FU) regimens in combination 
with leucoverin and oxaliplatin (FOLFOX) are the most common choice for stage III and 
high-risk stage II patients. In rectal cancer, neoadjuvant combined-modality therapy, 
including chemotherapy alone or in combination with radiation therapy, is often given to 
 T N M 
Stage 0 Tis N0 M0 
Stage I T1-T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4a N0 M0 
Stage IIC T4b N0 M0 
Stage IIIA 
T1-T2 
T1 
N1 
N2a 
M0 
M0 
Stage IIIB 
T3-T4 
T2-T3 
T1-T2 
N1 
N2a 
N2b 
M0 
M0 
M0 
Stage IIIC 
T4a 
T3-T4 
T4b 
N2a 
N2b 
N1-N2 
M0 
M0 
M0 
Stage IV 
Any T 
Any T 
Any N 
Any N 
M1a 
M1b 
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patients with late-stage disease before or after surgery to reduce local, and distant 
recurrence. Postoperative oxaliplatin-containing regimens such as FOLFOX are typically 
used in the setting of rectal cancer postoperatively (NCCN guidelines, 2015). 
Regarding the metastatic CRC (mCRC) systemic treatment, the chemotherapy 
options currently used are the FOLFOX regimen, the FOLFIRI regimen (leucovorin, 5-FU 
and irinotecan) and the CAPOX regimen (capecitabine and oxaliplatin), which have shown 
a comparable activity and efficacy as first-line treatments for mCRC, but have a different 
toxicity profile (Nallapareddy, 2011; Wolpin and Mayer, 2008). 
Moreover, there are three targeted monoclonal antibody therapies approved by the 
United States Food and Drug Administration (FDA) to treat patients with mCRC that can 
be used in combination or as single agents. This monoclonal antibodies are agents that 
act in two central cellular molecules: the vascular endothelial growth factor A (VEGF-A), 
targeted by bevacizumab, or the epidermal growth factor receptor (EGFR), targeted by 
cetuximab or panitumumab (Siegel et al., 2013; Nallapareddy, 2011). Their benefit was 
rapidly seen in combination with standard chemotherapy (Douillard et al., 2010; Saltz et 
al., 2008; Van Cutsem et al., 2009).  
 
7. Colorectal carcinogenesis 
The model of colorectal carcinogenesis by Fearon and Vogelstein in 1990 was the 
first multistep genetic model described based on the observation of specific genetic 
changes in benign and malignant lesions (Fearon and Vogelstein, 1990).  Some of the key 
features of this model is a result of four premises: (a) mutational activation of oncogenes 
along with mutational inactivation of key tumor suppressor genes plays a critical role in the 
development of CRC; (b) mutations in at least four to five genes are required for tumor 
formation to occur; (c) the total accumulation of genetic mutations as opposed to their 
specific order with respect to one another is the more critical event; and (d) mutant tumor 
suppressor genes have been shown to exert a biologic effect even when present in the 
heterozygote state (Chu, 2008). Following this, the genetic mutations that are necessary 
for the initiation and tumor progression in CRC occur among a variety of genes, such as 
adenomatous polyposis coli (APC), kristen rat sarcoma viral oncogene homolog (KRAS) 
and tumor protein p53 (TP53) (Ilyas et al., 1999). Only a fraction of adenomas progress to 
cancer, and progression probably occurs over years to decades. For instance, adenomas 
roughly 1cm in size may have an approximately 10 to 15% chance of progressing to 
carcinoma over a 5-20 year period (figure 5) (Berg and Søreide, 2011; Fearon, 2011; 
Fearon and Vogelstein, 1990; Kanthan et al., 2012; Markowitz and Bertagnolli, 2009; 
Søreide et al., 2009; Worthley et al., 2007).  
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Since the appearance of the model proposed by Fearon and Vogelstein in 1990 at 
least three distinct, but not mutually exclusive pathways have been described: 
chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator 
phenotype (CIMP) (Al-Sohaily et al., 2012; Kanthan et al., 2012; Worthley et al., 2007). 
 
7.1. Chromosomal instability (CIN) pathway 
Chromosomal instability (CIN) is the most common type of genomic instability 
observed, accounts for 70 to 85% of sporadic CRC (Markowitz and Bertagnolli, 2009; 
Perea et al., 2011). These tumors commonly are aneuploid, present chromosomal 
amplifications, high frequency of loss of heterozygosity (LOH), mutations in tumor 
suppressor genes and proto-oncogenes, such as APC, TP53, and KRAS, and frequent 
allelic loss at 18q. Causes leading to CIN are still unknown, but it was suggested that 
these may be related to defects in chromosome segregation, telomere dysfunction or 
defects in the DNA repair mechanisms. Some of the main karyotypic alterations present in 
the CIN pathway are gains on chromosomes 7, 8q and 13q, deletions on chromosomes 1, 
Figure 5 - Genetic model for colorectal tumorigenesis. The accumulation of mutations in 
oncogene and tumor suppressor genes, which is thought to contribute to tumor progression and 
the propensity to metastasize (adapted from Brown and DuBois, 2005). 
 
 
Figure 3 - Different genetic pathways in colorectal cancer pathogenesis. Three distinct 
parallel pathways are implicated in CRC pathogenesis: (A) Chromosomal Instability (CIN) pathway 
driven by inactivating mutations in tumor suppressor genes and activating mutations in proto-
oncogenes, (B) Microsatellite Instability (MSI) pathway characterized by inactivation of the 
mismatch repair (MMR) genes. The failure of MMR genes resulting in mutations in specific target 
genes involved in proliferation and cellular differentiation, and (C) Serrated Pathway (or CIMP) 
pathway driven by promoter hypermethylation of several genes and presenting BRAF mutation 
(adapted from Mundade et al., 2014).Figure 5 - Genetic model for colorectal tumorigenesis. 
The accumulation of mutations in oncogene and tumor suppressor genes, which is thought to 
contribute to tumor progression and the propensity to metastasize (adapted from Brown and 
DuBois, 2005). 
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4, 5, 8q, 18q and 17p, which contains the TP53 gene, and focal gains or losses in regions 
containing important cancer genes, such as vascular endothelial growth factor (VEGF), v-
myc avian myelocytomatosis viral oncogene homolog (MYC) and phosphatase and tensin 
homolog (PTEN) (Markowitz and Bertagnolli, 2009; Sheffer et al., 2009; Worthley et al., 
2007). 
APC mutations are an early event in CRC carcinogenesis and mutation frequency in 
sporadic adenomas varies from 30-70%, whereas in colorectal carcinomas it varies from 
60-80% (Worthley et al., 2007). This gene is described as a “gatekeeper” of cellular 
proliferation in CRC and is associated with both sporadic CIN CRCs and FAP (Al-Sohaily 
et al., 2012; Colussi et al., 2013; Ilyas et al., 1999; Worthley et al., 2007). This gene is 
involved in the Wingless-Type MMTV Integration Site Family (Wnt) signaling pathway and 
it is an important component of a degradation complex responsible for regulating β-
catenin levels. This is a multifunctional protein with important roles in Wnt signaling 
pathway: intercellular adhesion, cytoskeleton stabilization, cell cycle regulation, and 
apoptosis (Armaghany et al., 2012; Coppedè et al., 2014). Other genetic alterations 
involved in β-catenin regulation include gain-of-function mutations in its coding gene, the 
cadherin-associated protein beta 1 (CTNNB1), present in up to 50% of tumors lacking an 
APC mutation (Colussi et al., 2013; Kanthan et al., 2012; Pino and Chung, 2010). 
KRAS proto-oncogene encodes a signal transduction protein, which in its active 
state forms a complex with a guanosine triphosphate (GTP) group. This complex is 
inactivated by hydrolysis of GTP to guanosine diphosphate (GDP). The KRAS encodes a 
21 kDa protein involved in the G-protein signal transduction pathway, modulating cellular 
proliferation and differentiation. The frequency of mutations in the KRAS proto-oncogene 
in sporadic CRC is 30 to 50% (Calistri et al., 2005; Deschoolmeester et al., 2010). The 
most common mutations found in CRC are in exon 2 and to a lesser extent in exon 3 
(Calistri et al., 2005). If KRAS is mutated, the resulting complex is less sensitive to 
hydrolysis, remaining in a constitutively active state, leading to cell proliferation by a 
variety of signaling pathways, including the mitogen-activated protein kinases (MAPKs) 
pathway (Takayama et al., 2006).  
Another important event in CRC carcinogenesis is the occurrence of 18q deletion in 
50-70% of CRC cases (Armaghany et al., 2012). In this chromosomal region several 
important genes are located, such as SMAD family member 2 (SMAD2), SMAD family 
member 4 (SMAD4) and DCC netrin 1 receptor (DCC). The SMAD2 and the SMAD4 are 
transcription factors involved in the transforming growth factor β (TGF-β) signaling 
pathway, with importance in cell proliferation, differentiation, migration and apoptosis. The 
DCC gene encodes a transmembrane receptor of the immunoglobulin superfamily that 
promotes apoptosis when its ligand, Netrin-1, is absent (Al-Sohaily et al., 2012). 
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Additionally, TP53 gene is frequently mutated in CRC, and mutations in this gene are 
associated with the transition between late adenoma to carcinoma. The frequency of 
mutation in this gene in CRC is 35-75% (Naccarati et al., 2012). TP53 encodes a 
transcription factor with tumor suppressor activity, which activates a number of genes 
involved in cell cycle arrest, senescence, autophagy and apoptosis. When genetic 
damage occurs, DNA repair genes are activated (Armaghany et al., 2012; Iacopetta, 
2003). However, when the damage cannot be repaired, TP53 induces several pro-
apoptotic genes leading to cell death. Due to that characteristic, TP53 is often called 
“guardian of the genome” (Arends, 2013; Mills, 2005) (figure 6).  
 
 
 
7.2. Microsatellite instability (MSI) pathway 
The microsatellite instability (MSI) or “mutator” pathway is the other main 
mechanism for genomic instability in CRC (Worthley et al., 2007). Spread throughout the 
genome, there are short repeat nucleotide sequences that are prone to errors during 
Figure 6 - Different genetic pathways in colorectal cancer pathogenesis. Three distinct 
parallel pathways are implicated in CRC pathogenesis: (A) Chromosomal instability (CIN) 
pathway driven by inactivating mutations in tumor suppressor genes and activating mutations in 
proto-oncogenes, (B) Microsatellite instability (MSI) pathway characterized by inactivation of the 
mismatch repair (MMR) genes. The failure of MMR genes resulting in mutations in specific target 
genes involved in proliferation and cellular differentiation, and (C) Serrated pathway (or CIMP) 
driven by promoter hypermethylation of several genes and presenting BRAF mutation (adapted 
from Mundade et al., 2014). 
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replication, due to its repetitive nature. These sequences, named microsatellites, are 
present in both protein-coding and non-coding regions of the DNA. Those errors are 
recognized by the DNA Mismatch Repair (MMR) system, which is then responsible for 
repairing all base-base mismatches and ensuring a correct DNA synthesis during 
replication (Al-Sohaily et al., 2012; Kanthan et al., 2012). The MMR system is composed 
of multiple interacting proteins, such as mutS homolog 2 (MSH2), mutS homolog 3 
(MSH3), mutS homolog 6 (MSH6), mutL homolog 1 (MLH1), PMS1 homolog 1 (PMS1) 
and PMS1 homolog 2 (PMS2). Mutations in the genes encoding these proteins lead to the 
inactivation of the MMR system, which fails to repair these errors, causing their 
accumulation in repetitive sequences resulting in a widespread microsatellite instability 
(MSI) (Al-Sohaily et al., 2012; Ilyas et al.,1999; Kanthan et al.,2012; Markowitz and 
Bertagnolli, 2009). In order to assess the MSI tumor status, the Bethesda panel (BAT25, 
BAT26, D5S346, D2S123 and D17S250) was created to classify tumors, these can be  
classified as MSI-high (MSI-H, ≥30%) or MSI-low (MSI-L, <30%), and microsatellite stable 
(MSS, 0%)  (Boland et al., 1998). 
Besides being the hallmark of LS, the MSI pathway is also involved in the genesis of 
approximately 15% of sporadic CRC cases and is mostly caused by epigenetic silencing 
of the MLH1 gene promoter (Al-Sohaily et al., 2012; Bogaert and Prenen, 2014; Colussi et 
al., 2013; Kanthan et al., 2012). Tumors that develop through this pathway are more likely 
to arise in the proximal colon, are poorly differentiated and exhibit lymphocytic infiltrations 
and confer a better prognosis. The MSI is characterized by accumulation of mutations in 
microsatellite sequences that may occur in coding regions of several genes, such as 
transforming growth factor, beta receptor II (TGFBR2) and BCL2-associated X protein 
(BAX). TGFBR2 mutations are found in more than 80% of those cases, and inactivating 
mutations in this gene are involved in the adenoma transition to high-grade dysplasia or 
invasive carcinoma (Colussi et al., 2013; Kanthan et al., 2012) (figure 6). 
 
7.3. CpG island methylator phenotype (CIMP) pathway 
CpG island methylator phenotype (CIMP) pathway (also named serrated pathway) 
occurs in approximately 20 to 30% of CRC and it was reported that clinical features of 
CIMP CRCs are similar to those associated with MSI (Mundade et al., 2014). This 
pathway consists of the aberrant hypermethylation of the CpG dinucleotide sequences. 
This specific sites, the CpG islands, are regions containing high levels of cytosine-guanine 
pairs with phosphate bonds present in the genome (Perea et al., 2011). These regions are 
localized in the promoter regions of genes involved in several functions, such as cell cycle 
regulation, angiogenesis, DNA repair, invasion, adhesion or even apoptosis (Colussi et 
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al., 2013; Wong et al., 2007). In normal conditions, these CpG sites are unmethylated, 
and when methylation occurs it may inhibit gene expression and result in gene 
inactivation. Specific promoter methylation occurs, physiologically, to silence particular 
genes, while decontrolled methylation may occur pathologically as an important step in 
carcinogenesis. In fact, the epigenetic silencing of a gene by CpG island methylation is 
considered biologically equivalent to acquiring an inactivating mutation and it may occur 
as the first, second, or both hits in silencing tumor suppressor genes (Worthley et al., 
2007). In CRC, the influence of epigenetics is seen both by global hypomethylation of the 
genome and by hypermethylation of the promoter region of specific genes. This provides 
an alternative mechanism for loss of function of tumor suppressor genes, such as p16, 
APC, MLH1 and O(6)-methylguanine-DNA methyltransferase (MGMT) (Kanthan et al., 
2012).  
B-Raf proto-oncogene, serine/threonine kinase (BRAF), a member of the RAF 
kinase family, is a serine/threonine-specific protein kinase that plays a key role in 
regulating the mitogen-activated protein kinase/elk-related tyrosine kinase (MAPK/ERKs) 
signaling pathway, which is important to cell division, differentiation and secretion. The 
point mutation p.Val600Glu in BRAF (also described as V600E), leads to the constitutive 
activation of this kinase and to its insensitivity to negative feedback mechanisms, 
conducting to enhanced of the MAPK/ERK signaling. This overactive signaling cascade 
reaches cellular DNA within the nucleus and triggers downstream effectors to induce 
uncontrolled cell proliferation, evasion of immune response, angiogenesis, as well as 
resistance to apoptosis. This BRAF mutation is present in most CRCs with CIMP 
phenotype and those who do not have it may have a mutation in KRAS (Berg and 
Søreide, 2011; Markowitz and Bertagnolli, 2009; Worthley et al., 2007). 
It is possible to classify these tumors as CIMP-high (CIMP-H) or CIMP-low (CIMP-
L), based on the number of methylated markers, being the most common used the 
calcium channel, voltage-dependent, T type, alpha 1G subunit (CACNA1G), the insulin-
like growth factor 2 (IGF2), the neurogenin 1 (NEUROG1), the runt-related transcription 
factor 3 (RUNX3), and the suppressor of cytokine signaling 1 (SOCS1) (Al-Sohaily et al., 
2012; Colussi et al., 2013; Weisenberger et al., 2006). Most CIMP-H CRCs contain 
mutations in the BRAF gene, and usually are located in the proximal colon and confer 
poor prognosis (Bogaert and Prenen, 2014; Worthley et al., 2007). On the other hand, 
CIMP-L tumors are usually associated with KRAS mutation and MGMT methylation 
(Bogaert and Prenen, 2014;Colussi et al., 2013; Worthley et al., 2007) (figure 6). 
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8.  Hereditary colorectal cancer 
Colorectal cancer usually occurs in one of three patterns: inherited, familial and 
sporadic (Lynch and Shaw, 2013). The vast majority of CRCs are “sporadic” accounting 
for 60% of all CRC and comprising patients with no notable family history and, by 
definition, with no identifiable germline gene mutation. Sporadic cancers are caused by a 
series of genetic abnormalities in tumor suppressor genes and oncogenes that give cells 
an evolutionary advantage over their neighbors and arise at a median age of 70-75 years 
(figure 7) (Kheirelseid et al., 2013). Familial CRC occurs in an estimated 30% of the cases 
and refers to patients who have at least one blood relative with CRC or an adenoma, but 
with no specific germline mutation or clear pattern of inheritance (figure 7) (Kheirelseid et 
al., 2013). 
Hereditary CRC syndromes are responsible for about 10% of all CRC cancers, 
which result from germline inheritance of mutations in highly penetrant cancer 
susceptibility genes (figure 7) (Jasperson et al., 2010; Rustgi, 2007). The most common 
hereditary CRC syndromes identified so far are Lynch syndrome (LS), familial 
adenomatous polyposis (FAP), MUTYH associated polyposis (MAP), and the 
hamartomatous polyposis syndromes Peutz-Jeghers syndrome (PJS), juvenile polyposis 
syndrome (JPS) and Cowden syndrome (Al-Sohaily et al., 2012; Lynch and Shaw, 2013; 
Zbuk and Eng, 2007). 
Figure 7 - Circle graph depicting the marked genotypic and phenotypic heterogeneity in 
hereditary colorectal cancer syndromes.  AC-1, Amsterdam Criteria 1; MMR, mismatch repair; 
FAP, familial adenomatous polyposis; AFAP, attenuated familial adenomatous polyposis; HBCC, 
hereditary breast and colorectal cancer; PJS, Peutz-Jeghers syndrome; FJP, familial juvenile 
polyposis; CD, Cowden’s disease; BRRS, Bannayan-Ruvalcaba-Riley syndrome (adapted from 
Lynch and Shaw, 2013).  
 
 
Figure 7 - Circle graph depicting the the marked genotypic and phenotypic heterogeneity 
in hereditary CRC syndromes.  AC-1, Amsterdam Criteria 1; MMR, mismatch repair; FAP, 
familial adenomatous polyposis; AFAP, attenuated familial adenomatous polyposis; HBCC, 
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8.1. Lynch syndrome 
Lynch syndrome is an autosomal dominant disease caused by heterozygous loss-
of-function germline mutations in DNA MMR genes, most frequently in MLH1 or MSH2, 
which account for approximately 90% of the all mutations. Mutations in MSH6 and PMS2 
have collectively been associated with a small percentage of LS cases (Hitchins et al., 
2005; Hitchins et al., 2007). However, the tumors in LS only occur after somatic biallelic 
gene inactivation resulting in total loss of DNA MMR activity (Giardiello et al., 2014). This 
syndrome is recognized as the most common hereditary CRC, accounting for nearly 2-5% 
of all colorectal malignancies (Lynch et al., 2015). The lifetime risk of CRC in patients with 
the recognized LS-related mutations may be as high as 70 to 80% (Gryfe, 2009; Pande et 
al., 2012).  
Patients with LS develop CRC at a younger age than the general population (~45 
vs. 65 years), develop predominantly proximal colon cancers, and are at a higher risk for 
synchronous CRCs and extra-colonic tumors (including endometrial, ovarian, gastric, 
small bowel, pancreatic, hepatobiliary, skin, brain, and urethral tumors) (Pande et al., 
2012). A genotype-phenotype correlation has been observed in which MLH1 mutation 
carriers are at higher risk of young onset CRC cancer, MSH2 at higher risk of extracolonic 
cancers, MSH6 at increased risk of endometrial cancer, and PMS2 carriers show a lower 
absolute lifetime risk of CRC and endometrial cancer (15-20%) compared with other 
mutation carriers (Balmaña et al., 2013). 
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Table 3 - Revised minimum criteria for clinical definition of Lynch syndrome. 
 
 
The clinical diagnosis of LS is based on the Amsterdam or on the Bethesda criteria 
(table 3) (Guidelines NCCN, 2015). The Amsterdam criteria are very specific, but too 
stringent (low sensitivity) and there are several studies that have shown that 40% of LS 
families with an identified gene mutation did not meet Amsterdam criteria (Kastrinos and 
Syngal, 2011). Bethesda guidelines were developed to improve the sensitivity, although 
they have a lower specificity and require a prescreening by tumor molecular testing either 
looking for MSI or abnormal immunohistochemistry (IHC) to detect altered expression of 
MMR proteins (Umar et al., 2004).  
 
 
  
Amsterdam Criteria II (adapted from Vasen et al., 2007) 
 
At least three relatives must have a cancer associated with LS*, all of the following criteria 
should be present: 
One must be a first degree relative of the other two; 
At least two successive generations must be affected; 
At least one relative with cancer associated with LS should be diagnosed before age 50 
years; 
FAP should be excluded in the CRC cases(s) (in any); 
             Tumors should be verified by histopathological examination. 
 
Bethesda Criteria (Revised) (adapted from Umar et al., 2004) 
 
CRC diagnosed in a patient aged <50 years;  
Presence of synchronous, metachronous or other  Lynch syndrome-related tumors, 
regardless of age; 
CRC with MSI-H phenotype diagnosed in a patient aged <60 years, with specific 
pathological features; 
Patient with CRC and a first-degree relative with a Lynch syndrome-related tumor#, with one 
of the cancers diagnosed at age <50 years; 
Patient with CRC with two or more first degree or second-degree relatives with a Lynch 
syndrome-related tumor regardless of age. 
* Lynch syndrome-associated cancer includes those of endometrium, small bowel, ureter or renal pelvis. 
# Lynch syndrome-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter, 
renal pelvis, biliary tract and brain tumors, sebaceous gland adenomas and carcinoma of the small bowel. 
 
 
* Lynch syndrome-associated cancer includes those of endometrium, small bowel, ureter or renal pelvis. 
# Lynch syndrome-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter, 
renal pelvis, biliary tract and brain tumors, sebaceous gland adenomas and carcinoma of the small bowel. 
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8.2. The MMR system  
 Lynch syndrome is characterized by germline mutations in the MMR genes. The 
human MMR system recognize errors in the DNA nucleotide sequence by matching the 
complementary chromosome strands and repairs base-base mismatches that occur 
during DNA replication in proliferating cells. There are several human MMR proteins, 
including human homologs of MutS, MutL, exonuclease 1 (EXO1), single-strand DNA-
binding protein replication protein A (RPA), proliferating cellular nuclear antigen (PCNA), 
DNA polymerase δ (POLD)/DNA polymerase ε (POLE) and DNA ligase I (figure 8) (Jun et 
al., 2006). Human MutS and MutL homologues are heterodimers and MSH2 
heterodimerizes with MSH6 or MSH3 to form MutSα or MutSβ, respectively, both of which 
are ATPases that play a critical role in mismatch recognition and initiation of repair. The 
MutSα preferentially recognizes base-base mismatches and insertion/deletion (ID) 
mispairs of one or two nucleotides, while MutSβ preferentially recognizes larger ID 
mispairs. The MLH1 heterodimerizes with PMS2, PMS1, or MLH3 to form MutLα, MutLβ, 
or MutLγ, respectively. The MutLα is required for MMR activity and the MutLγ plays a role 
in meiosis, but no specific biological role has been identified for MutLβ. The MutLα 
possesses an ATPase activity and defects in this activity inactivate the MMR system in 
human cells. In a reconstituted human MMR system, MutLα regulates termination of 
mismatch-provoked excision. PCNA interacts with MSH2 and MLH1 and is thought to play 
important roles in the initiation and DNA resynthesis steps of MMR. PCNA also interacts 
with MSH6 and MSH3 via a conserved PCNA interaction motif termed the PIP box. RFC 
that is bound at the 5′ terminus of the discontinuity prevents degradation in the 5′→3′ 
direction (away from the mismatch). Once the mismatch is removed and the EXO1 activity 
is inhibited by bounding to RPA and MutLα, the gap is filled by Pol δ. DNA ligase I seals 
the remaining nick to complete the repair process (Rasmussen et al., 2012) (figure 8). 
Cells with biallelic mismatch repair gene mutations cannot repair spontaneous DNA errors 
and progressively accumulate mutations with succeeding DNA replications throughout the 
genome, resulting in genetic instability (Jiricny, 2006; Martín-López and Fishel, 2013). 
Development of mismatch repair-deficient cancers exhibiting microsatellite instability 
(MSI) occurs with the loss-of-function of the remaining normal allele of the affected gene 
within somatic tissues (Crépin et al., 2012).  
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9. The role of epigenetics in Lynch syndrome 
In the past decade, another distinct mechanism affecting the two key MMR genes 
MLH1 and MSH2, was unraveled in a subset of patients meeting the clinical criteria for LS 
without a germline MMR mutation, termed as ‘‘constitutional epimutation’’, or just 
‘‘epimutation” (Castillejo et al., 2015; Hitchins and Ward, 2009). In this mechanism, the 
expression of either of these two genes is interrupted within normal tissues via promoter 
constitutional methylation instead of a direct genetic alteration (Hitchins, 2013; Lynch et 
al., 2015). These gene expression changes are brought about by the addition of various 
biochemical modifications to the DNA backbone, which include methylation of cytosine 
 
 
Figure 8 - Steps in MMR system. The replicative DNA polymerase misincorporates a nucleotide 
during DNA replication. The MSH2-MSH6 heterodimer recognizes and binds to the mismatch, 
followed by mismatch validation by ADP → ATP exchange. This complex recruits the MLH1-PMS2 
heterodimer that, in turn, exchanges ADP for ATP. The latent endonuclease activity of PMS2 
introduces a nick in the daughter strand, 5’ of the misincorporation. The nick serves as entry point 
for the exonuclease 1 (EXO1) that degrades a patch of the daughter strand that includes the 
misincorporation. The remaining single-stranded DNA gap is covered by the single-strand DNA 
binding protein replication protein A  (RPA) and filled by the replicative DNA polymerase (adapted 
from Rasmussen et al., 2012). 
 
 
Figure 4 - Detailed methylation patterns of MLH1 promoter, assessed by MS-MLPA. The five 
regions of the CpG islands targeted by the selected probes are shown (adapted from Gausachs et 
al., 2012). Yellow rectangle highlight the most important regions. 
 
Figure 8 - Steps in MMR system. The replicative DNA polymerase misincorporates a nucleotide 
during DNA r plicati n. The MSH2-MSH6 heterodimer recognizes and bind  to the mismatch, 
f llowed by mis a ch validation by ADP → ATP exchange. This complex recruits the MLH1-PMS2 
heterodimer that, in turn, exchanges ADP for ATP. The latent endonuclease activity of PMS2 
introduces a nick in the daughter strand, 5’ of the misincorporation. The nick serves as entry point 
for the exonuclease 1 (EXO1) that degrades a patch of the daughter strand that includes the 
misincorporation. The remaining single-stranded DNA gap is covered by the single-strand DNA 
binding protein replication protein A  (RPA) and filled by the replicative DNA polymerase (adapted 
from Rasmussen et al., 2012). 
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bases within cytosine-guanine dinucleotides (CpG), modifications to the histone core of 
the nucleosomes, as well as the positioning of nucleosomes along the DNA sequence. 
Methylation of clusters of CpG sites spanning the gene promoter (CpG islands) will be the 
sole chromatin modification referred to since this is the most easily and frequently studied 
of all epigenetic marks, and is a clear characteristic of a gene that has been epigenetically 
silenced (Dawson and Kouzarides, 2012; Herceg and Vaissière, 2011). 
Constitutional epimutations of the MSH2 gene are secondary to germline deletions 
in the EPCAM gene in cis, being transmitted in an autosomal dominant inheritance 
(Ligtenberg et al., 2009). However, constitutional epimutations of the MLH1 gene are 
more variable, and the pattern of transmission of these distinct forms of MLH1 epimutation 
presumably reflects their mechanistic basis (Castillejo et al., 2015; Hitchins, 2013). 
 
9.1. Constitutional epimutation of MLH1 
The MLH1 gene is located on the short arm of chromosome 3 at position p21.3. The 
MLH1 gene is 72,558 bases in length and consists of 19 coding exons; the translated 
protein contains 756 amino acids. The protein MLH1 dimerizes mainly with the protein 
product of the PMS2 gene to coordinate the binding of other proteins involved in MMR 
system, as referred previously (Hegde et al., 2014). 
The first case to be identified with constitutional epimutation of MLH1 was described 
by Gazzoli and coworkers in 2002. They recognized the presence of dense methylation of 
a single allele of the MLH1 promoter in the peripheral blood lymphocytes (PBL) of a 
patient who had developed a CRC demonstrating MSI and MLH1 loss at age of 25 years 
(Gazzoli et al., 2002; Vasen et al., 2013). Since MLH1 inactivation follows Knudson’s two-
hit-model, the observed loss of heterozygosity of the unmethylated allele in the tumor of 
this patient provided the first signal that these epigenetic aberrations in normal tissues 
could predispose to LS (Gazzoli et al., 2002; Hitchins, 2013). 
Although these epigenetic silencing mechanisms are quite distinct from germline 
sequence mutations, they also confer an elevated risk of developing mismatch repair 
deficient tumors at a young age of onset (Lynch et al., 2015). They therefore represent an 
alternative etiological mechanism to genetic mutation for this cancer predisposition 
syndrome (Hitchins, 2010). The MLH1 epimutation may be dichotomized into two 
categories: (1) those that tend to arise spontaneously and are reversible between 
generations, though occasionally transmitted to the next generation in a non-Mendelian 
pattern (primary MLH1 epimutation); and (2) Mendelian epimutations that follow a classic 
autosomal dominant inheritance pattern due to an underlying cis-genetic cause 
(secondary/genetically facilitated MLH1 epimutation).  
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Since a single parental allele is affected, it has been proposed that MLH1 
epimutations may originate in the germline. Certainly the demonstration that monoallelic 
promoter methylation is present in tissues derived from all three embryonic germ cell 
lineages strongly suggests that MLH1 epimutations are already present in the early 
embryo, prior to the differentiation of the germ cell layers (Goel et al., 2011). 
 According to the study of Hitchins and coworkers, the mature spermatozoa, from 
four MLH1 epimutation carriers with apparent soma-wide epimutation, showed absence of 
this alteration (Hitchins, 2013). Interestingly, in the majority of sporadic cases studied, in 
whom the epimutation has arisen de novo in the proband, MLH1 epimutation tended to 
occur on the maternal MLH1 allele. Therefore, it remains plausible that some MLH1 
epimutations occur in the oocyte. The precise timing and cellular origin of this defect 
remains to be determined and may even differ from one case to another. On the other 
hand, a certain degree of allelic epigenetic mosaicism has been observed in most carriers, 
since the affected allele remains unmethylated or partially methylated in a proportion of 
somatic cells, whilst other copies are fully methylated (Seisenberger et al., 2012; Kwok et 
al., 2014; Pineda et al., 2012). 
 
9.2. Importance of MLH1 epimutations in clinical practice 
Constitutional MLH1 epimutation are infrequent in comparison to the incidence of 
germline MMR mutations and with sporadic CRC demonstrating MSI. Nevertheless, this is 
an etiological mechanism that confers a high risk of development LS-type cancers in 
carriers (Lynch et al., 2015). Given that molecular diagnosis is important to identify these 
carriers and to provide (and to their family members) an appropriate clinical surveillance 
(Hitchins, 2013), it is important not only to identify an epimutation as the cause for cancer 
susceptibility, but also to define the type of epimutation (that is its mechanistic basis), 
since this will dictate its risk of intergenerational inheritance (Goel et al., 2011). It is 
therefore opportune that screening for this etiological mechanism is implemented on a 
molecular diagnostic routine basis. It is important to establish a consensus selection, and 
an efficient diagnostic assay. Testing for MLH1 epimutation on a triaged basis by 
incorporating this into existing algorithms for patient inclusion and molecular detection of 
constitutive MMR defects might be improved (Banno et al., 2012; Hitchins, 2013).
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II. AIMS OF THE STUDY 
 
There are several families that fulfill the clinical criteria for Lynch syndrome and do 
not present any MMR germline mutation. Given that, it is important to characterize these 
families.   
Essentially, the specific aims of this work were: 
 
 To investigate the prevalence of MLH1 constitutional methylation in a series of 
CRC patients with no expression of the MLH1 protein in the tumor and with no 
MLH1 germline mutation;  
 Deduce the pattern of constitutional methylation inheritance in Lynch syndrome 
families; 
 To establish the correlation between MLH1 constitutional epimutation and family 
history and tumor phenotype. 
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III. MATERIALS AND METHODS 
 
1. Patients and samples collection 
A consecutive series of PBL samples from 38 patients (index cases) 17 males 
(44.7%) and 21 females (55.3%) fulfilling the clinical criteria for LS with colorectal 
carcinomas where included. All patients presented loss of MLH1 protein expression 
and had no MLH1 pathogenic germline mutation identified, this is shown in table 4. 
These patients were diagnosed and surgically treated at the Portuguese Institute of 
Oncology-Porto assessed through Genetic Cancer Counselling, and referred to the 
Genetics Department between 1997 and 2014.  Three of these patients (3/38; 7.9%) 
presented the p.Val600Glu BRAF mutation in their tumors. The majority of these 
patients (37/38; 97.4%) met the Bethesda criteria and one patient (1/38; 2.6%) met the 
Amsterdam criteria. Clinico-pathological information was obtained from medical records 
(table 4). 
Whenever possible, family members of the index patients were also studied, and, 
when available, swab buccal samples and paraffin embedded tissue samples (with 
different germ layers origins) were also analyzed in patients harboring constitutional 
epimutation. 
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Table 4 - Clinico-pathological data of 38 index cases fulfilling the clinical criteria for Lynch syndrome. 
Patient Gender Tumor localization (diagnosis age) IHC MMR Clinical Criteria BRAF 
#1 F Ascending colon (40) MLH1/PMS2 absence BC NA 
#2 F 
Stomach (75)  
Cecum (75) 
Breast (78) 
MLH1 absence* BC NA 
#3 M Descending colon (38 and 48) MLH1 absence* BC WT 
#4 M Ascending colon (25) MLH1/PMS2 absence BC WT 
#5 M Sigmoid colon (51) MLH1/PMS2 absence BC WT 
#6 M Rectum (53) MLH1/PMS2 with decreased immunoreactivity BC WT 
#7 M Ascending colon (43) MLH1/PMS2 absence BC WT 
#8 F Rectum (16) MLH1 absence (normal PMS2) BC WT 
#9 F Rectum (43) MLH1 absence* BC V600E 
#10 F 
Ascending colon (26) 
Stomach (60) 
MLH1/PMS2 absence BC WT 
#11 M Ascending colon (65) MLH1/PMS2 absence BC WT 
#12 F Ascending colon (62) MLH1/PMS2 absence BC WT 
#13 M Sigmoid colon (44) MLH1/PMS2 absence BC WT 
#14 F Ascending colon (69) MLH1/PMS2 absence BC WT 
#15 F Uterus and ovary  (38) MLH1/PMS2 absence BC WT 
#16 F 
Breast (60) 
  Ascending colon  (66) 
MLH1/PMS2 absence BC WT 
#17 M Ascending colon (25) MLH1/PMS2 absence BC WT 
#18 M Sigmoid colon (43) MLH1/PMS2 absence BC NA 
#19 M Sigmoid colon (47) MLH1/PMS2 absence BC WT 
#20 M Ascending colon (23) MLH1/PMS2 absence BC WT 
#21 F 
Endometrium (57) 
Ascending Colon  (74) 
MLH1/PMS2 absence BC V600E 
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Lung (74) 
#22 F Sigmoid colon (47) MLH1/PMS2 absence BC WT 
#23 F Ascending colon (59) MLH1/PMS2 absence BC WT 
#24 M 
Rectum (45) 
Ascending colon (61) 
MLH1/PMS2 absence BC WT 
#25 F 
Ascending colon (62) 
Endometrium (63) 
MLH1/PMS2 absence BC WT 
#26 F Ascending colon (41) MLH1/PMS2 absence BC WT 
#27 M Rectum (33) MLH1/PMS2 absence BC WT 
#28 F Stomach (78) MLH1/PMS2 absence BC WT 
#29 F Breast (30) MLH1/PMS2 absence# AC WT 
#30 M Sigmoid colon (61) MLH1/PMS2 absence BC WT 
   #31 F Descending colon (65) MLH1/PMS2 absence BC V600E 
#32 F Ascending colon (54) MLH1/PMS2 absence BC WT 
#33 F Ascending colon (42) MLH1/PMS2 absence BC NA 
#34 M Ascending colon (60) MLH1/PMS2 absence BC WT 
#35 M Ascending colon (44) MLH1/PMS2 absence BC NA 
#36 F Endometrium (50) MLH1/PMS2 absence BC WT 
#37 F Sigmoid colon (56) MLH1/PMS2 with decreased immunoreactivity BC WT 
#38 M 
Ascending colon (48)  
Transverse colon (48) 
Descending colon (48) 
MLH1/PMS2 absence BC WT 
 
         AC, Amsterdam criteria; BC, Bethesda criteria; F, female; M, male NA, not analyzed. 
        *The analysis was not performed for PMS2.   
         #IHC was performed on tumor of a relative.
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2. DNA and RNA extraction from peripheral blood samples 
Peripheral blood samples were collected in sterile tubes containing EDTA 
anticoagulant. In order to achieve the lysis of erythrocytes, a hypotonic solution was 
added (AKE: NH4Cl [Merck, Darmstadt, Germany] 155 mM; KHCO3 [Merck] 10 mM; EDTA [Sigma-Aldrich, 
Steinheim, Germany] 0.1 mM; pH=7.4) at 3-5 mL of blood in a ratio of 9 to 10 times this 
volume, followed by incubation at 4°C for 30 minutes. The samples were then 
centrifuged at 1500g [Sigma centrifuge 4K15]. The supernatant was removed and the procedure 
was repeated as described above until the pellet was free of hemoglobin. The cell 
pellet was resuspended in 1 mL of PBS [Merck], transferred to a microcentrifuge tube and 
centrifuged at 3000g. The supernatant was removed and the cell pellet was stored at 
4°C for until DNA and/or RNA extraction.  
DNA was obtained using the Magna Pure LC 2.0 [Roche Applied Science, Indianapolis, Indiana], 
and total RNA extraction was performed using TRIzol® Reagent [Invitrogen Carlsbad, CA, USA] 
according to the manufacturer’s instructions and standard protocol (Chomczynski, 
1993). DNA and RNA quality and concentration was evaluated using a NanoDrop ND-
1000® [NanoDrop Technologies, Wilmington, DE, USA]. 
 
3. DNA extraction from formalin-fixed paraffin-
embedded tissue 
Tumor areas containing at least 50% of tumor cells were delimited, by a 
pathologist, in the hematoxylin and eosin (H&E) stained slides of each sample. The 
corresponding unstained slides were immersed in xylene [Sigma] and twice in ethanol 
100% [Merck] for 5 minutes, each. Tumor and normal areas, which were previously 
delimited by comparison with the correspondent H&E stained slides, were 
macrodissected and transferred to a centrifuge tube. DNA was isolated using the 
QIAamp® DNA FFPE Tissue Kit [Qiagen, Hilden, Germany], following manufacturer’s 
instructions. Finally, DNA was quantified by spectrophotometry with NanoDrop ND-
1000®. 
4. DNA extraction from buccal mucosa swabs 
The buccal mucosa swabs were collected and preserved in dry medium. PBS 
[Merck] (1 mL) was added and, after incubation of 3 hours at 4ºC, the samples was 
centrifuged for 10 minutes at 3000g. After centrifugation, 4 mL of SE [Merck], 400 µL SDS 
[Gibco Invitrogen, Carlsbad, CA, USA] and 50 µL of proteinase K [Gibco, Invitrogen] were added, and the 
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mixture was incubated overnight at 55 ºC. After incubation, 1 mL of NaCl 6M [Merck] was 
added followed by 10 minutes of incubation at 55 ºC. One equivalent volume of 
chloroform was added, the mixture was homogenized during 30 minutes, and 
centrifuged for 10 minutes at 3000g, to separate the different phases. The upper phase 
was collected to a new tube and an equal volume of isopropanol [Merck] was added. DNA 
was isolated after 10 minutes of centrifugation at 3000g. The supernatant was 
discarded and 3 mL of ethanol 70% [Merck] was added to wash the DNA during 
incubation overnight at 4ºC. After this, the DNA was centrifuged for 10 minutes at 
3000g, the supernatant was discarded and the DNA was dry out at 50ºC for about 3 
hours. DNA was eluted with 200-300μL of nuclease-free water [Quiagen] and incubated for 
an additional 10 minutes at 50ºC. Finally, the DNA was quantified by 
spectrophotometry with NanoDrop ND-1000®. 
5. MLH1 methylation analysis 
Analysis of MLH1 promoter methylation was performed on PBL DNA of the index 
patients. Methylation testing was performed by methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) using the SALSA MS-MLPA ME011-B1 kit 
[MRC Holland, Amsterdam, Netherlands], according to the manufactures instructions. This method 
allows the detection of methylation patterns in a number of tumor suppressor genes in 
addition to the semi-quantification of the copy number of sequences analyzed. Some 
key considerations need to be taken into account when designing or adopting an assay 
for screening of patients for the presence of MLH1 promoter constitutional epimutation. 
The molecular method employed needs to be sufficiently sensitive to detect 
methylation levels down to 5% or below, in order to detect cases with a mosaic form of 
epimutation (Hitchins and Ward, 2009; Ward et al., 2012). Furthermore, the assay 
should target specific CpG sites within the MLH1 promoter, namely, the C- or D-Deng 
regions, since these have been correlated most closely with the loss of transcription 
and are less susceptible to age-related or other non-specific methylation (Deng et al., 
2002).  
In MS-MLPA, the ligation of MLPA probes is combined with digestion of the 
genomic DNA with the methylation sensitive endonuclease HhaI and comparing the 
undigested MLPA essay (Nygren et al., 2005). The ME011-B1 MMR probemix has 
been developed to detect aberrant CpG islands methylation of MMR genes and 
includes 6 probes for MLH1 that contain a digestion site specific for the methylation-
sensitive HhaI enzyme. The six probe pairs in MLH1 promoter (with the respective 
HhaI sites located at -659,-518, -382, -246, -13 and +206 relative to the start codon; 
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GenBank accession number NM_000249.3) covers independent regions: regions A to 
D of the promoter and intron 1 (Deng et al., 2002). The most important methylation 
region for MLH1 expression, the C- Deng region, is from -248 to -178nt before the 
transcription site. The transcription start site that Deng used for reference lies 21nt 
before the start codon. The second most important region, the D- Deng region, is from  
-9 to +15nt (Deng et al., 1999). 
The samples were analyzed on an ABI PRISMTM 310 Genetic Analyzer [Applied 
Biosystems, Foster City, CA, USA].  For this propose, about 0.5 µL of the MS-MLPA reaction 
product was added to 15 µL of Hi-DiTM Formamide [Applied Biosystems], and to 0.4 µL of Gene 
Scan ROX (Carboxy-X-Rhodamine) size standard [Applied Biosystems]. Fluorescently labeled 
products from MS-MLPA reactions were analyzed using the Gene Mapper® software, 
version 3.7 [Applied Biosystems]. Electropherogram plots of each sample were analyzed 
manually.  
Whenever possible, swab buccal samples and paraffin embedded tissues were 
analyzed for MLH1 promoter methylation using the same approach. 
Three independent MS-MPLA reactions were performed in all samples and the 
average percentage of methylation in the more important regions of the MLH1 were 
calculated using Microsoft Office Excel 2003TM and according to the manufacture’s 
protocol (Joensuu et al., 2008; MRC-Holand, 2012). 
 
6. MLH1 promoter sequencing 
Screening for mutations within the MLH1 promoter (that may affect the binding of 
MLPA probes) was performed by Sanger sequencing in the 38 peripheral blood 
samples and using two sets of primers, according to Pineda et al (2012) (table 5). For 
this purpose, DNA was amplified in a solution containing 1x Taq reaction buffer [Thermo 
Fisher Scientific, Rockford, USA] (75mM Tris-HCl, 20 mM (NH4)2SO4), 1.25 mM of MgCl2 [Thermo Fisher 
Scientific], 0.5 mM dNTP mix [Thermo Fisher Scientific], 0.33 mM of each primer (reverse and 
forward) [Frilabo, Portugal], 1 U of Taq DNA polymerase [Thermo Fisher Scientific] and bidestilled 
sterile water [B. Braun, Foster City, CA, USA] in a final reaction volume of 30 µL. PCR reaction was 
performed in a termocycler [Perkin-EImer, Gene Amp PCR Systern 9700, Waltham, Massachusetts, U.S] according 
to the following conditions: an initial denaturation step at 95°C for 10 min, followed by 
35 cycles of 95°C for 45 seconds, annealing step at 58°C for 45 seconds and a 45 
seconds extension step at 72°C. A final extension step was done at 72°C for 10 min. 
Amplified products were then analyzed by electrophoresis in a 2% (w/v) agarose gel 
[Gibco BRL] stained with green safe 0.05 µL/mL  [Sigma].  
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 Subsequently, the PCR products were purified using the ExoSAP-IT method for 
the removal of primers and dNTPs in excess. Samples were purified adding 2 µL of 
ExoSAP solution (Exonuclease I [Thermo Fisher Scientific] (20 U/μL) and Fast Thermosensitive 
Alkaline Phosphatase [Thermo Fisher Scientific] (1 U/μL), in a proportion of 1:2) to 5 µL of PCR 
product, followed by incubation at 37ºC for 50 minutes, and enzyme inactivation at 
80ºC for 15 minutes. 
 The purified PCR products were sequenced using BigDye® Terminator v1.1 or 
v3.1 Sequencing Kits [Applied Biosystems], and according to manufactors instructions. In order 
to remove excess of dNTPs, labeled ddNTPs and non-incorporated primer, the 
sequencing products were purified with IIlustra Sephadex® G-50 fine [GE Healthcare, Life 
Sciences, Cleveland, USA], according to standard procedure. After purification, 12 μL of Hi-DiTM 
Formamide [Applied Biosystems, Foster City, CA, USA] were added to the products to help stabilize 
the single stranded DNA (ssDNA). The products were then analyzed in either an ABI 
PRISMTM 310 Genetic Analyzer or a 3500 Genetic Analyzer [Applied Biosystems] by capillary 
electrophoresis. The electropherograms of each sample were analyzed with the 
Sequencing Analysis Software v5.4 [Applied Biosystems]. All of them were read at least twice, 
reviewed manually and with the Mutation Surveyor® DNA Variant Analysis Software 
v4.0.8 [Softgenetics, State College, PA, USA]. 
 
7. MLH1 transcript quantification 
The MLH1 transcripts were quantified by semiquantitative multiplex RT-PCR. For 
this propose, we amplified simultaneously a control transcript, the β2-microglobulin 
(B2M), and part of the MLH1 transcript, using flurescence-labeled primers designed in 
the Primer-BLAST (Basic Local Alignment Search Tool) program (table 5) and 
according to the QIAGEN OneStep RT-PCR Kit [Qiagen]. Semiquantitative RT-PCR 
products were analyzed by fragment analysis on an ABI PRISMTM 310 Genetic 
Analyzer using the same conditions described above for the methylation analyses. 
MLH1 transcript levels were calculated by comparing the relative peak areas of the 
patients to the relative peak areas of the controls.   
Four independent reactions of semiquantitative multiplex RT-PCR were 
performed in all cases with constitutional methylation and controls. It was then 
calculated the average percentage of the decrease of MLH1 transcript levels. 
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 Table 5 - Primer sequences for MLH1 promoter sequencing and primer sequences for 
rs1799977 in cDNA and gDNA MLH1 gene. 
       # 6-FAM, 6- Carboxyfluorescein. 
 
 
8. Screening of the MLH1 c.655A>G SNP  
Screening of the MLH1 c.655A>G SNP (rs1799977), within exon 8, was 
performed by Sanger sequencing in DNA and RNA samples from the index patients 
harboring MLH1 constitutional methylation.  
Briefly, the genomic DNA (gDNA) was amplified for MLH1 exon 8, using a PCR 
reaction containing 1x Taq reaction buffer [Thermo Fisher Scientific] (75 mM Tris-HCl, 25 mM 
(NH4)2SO4), 2.5 mM of MgCl2 [Thermo Fisher Scientific], 0.8 mM dNTP mix [Thermo Fisher Scientific], 2 
mM of each primer (reverse and forward) [frilabo], 0.75 U of Taq Gold DNA polymerase 
[Thermo Fisher Scientific]  bidestilled sterile water, in a final reaction volume of 25 µL. PCR 
reaction was performed in a termocycler [Perkin-EImer, Gene Amp PCR Systern 9700] according to the 
following conditions: an initial denaturation step at 95°C for 10 min, followed by 35 
cycles of 95°C for 45 seconds, annealing step at 58°C for 45 seconds and a 45 
seconds extension step at 72°C. A final extension step was done at 72°C for 10 min. 
The RNA was amplified using the same primers (not labeled) as for semiquantitative 
MLH1 RT-PCR amplification and according to the QIAGEN OneStep RT-PCR Kit. 
Gene Analysis Primer name Forward primer (5'-3') Reverse  primer (5'-3') Ta (º C) 
MLH1           
 
Promoter  
sequencing 
MLH1 promoter  
 
AACCCTTTCACCATGCT 
CTG 
 
TGAAGAGAGAGCTGCTC 
GTG 
59/58 
MLH1 promoter  
 
TACATGCTCGGGCAGTA 
CCT 
 
CCTCGTGCTCACGTTC 
TTC 
59 
gMLH1 ex7_8  
 
TGGGTAAAATATTAATAG 
GCTGTATGG 
 (6-FAM)#   
AAGGTTCCAAAATAATG 
TGATGG 
58 
 
 
RT 
amplification  
 
RT_MLH1 ex6_9 
GGAAGTTGTTGGCAGG 
TATTCA 
CCATTCATTTTGAAGGC 
TAGGGT 
54 
 
 
ASE 
(SNuPE) 
MLH1 rs1799977  
GTGGACAATATTCGC 
TCC 
ACTAACAGCATTTCCAA 
AGA 
54 
B2M  B2M 
 
CCTCCATGATGCTGCTTA 
CATGTC 
(6-FAM)# 
ATGTCTCGCTCCGTGGCC 
TTAGCT 
58 
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All PCR and RT-PCR products were then analyzed by electrophoresis in a 2% 
(w/v) agarose gel stained with green safe 0.05 µL/mL, purified and sequenced as 
described above. 
 
9. MLH1 allelic expression analysis  
For allelic expression analyses of the rs1799977 in heterozygous patients, the 
relative levels of the A/G alleles were determined in genomic DNA and RNA by single-
nucleotide primer extension (SNuPE). Briefly, genomic DNA and total RNA were 
amplified using the same approach as for rs1799977 sequencing. After amplification, 
and standard ExoSAP-IT purification, the SNuPE reaction and capillary electrophoresis 
was performed following the SNaPshot Kit [Applied Biosystems] manufacturer´s protocol. 
Four independent reactions of allelic expression of the relative levels of the A/G 
alleles were determined in gDNA and cDNA of heterozygous patients (cases and 
controls) and the average percentage of the decrease in the allele relative areas were 
calculated. 
 
10. Study of microsatellite instability 
Microsatellite instability was performed using the Bethesda panel (BAT25, 
BAT26, D2S123, D5S346 and D17S250), according to the 1997 National Cancer 
Institute Guidelines (Boland et al., 1998) using fluorescence labeled primers (Dietmaier 
et al., 1997). The amplification reaction occurred in a total volume of 20 µL of a solution 
containing: 1x Taq reaction buffer [Thermo Fisher Scientific] (75mM Tris-HCl, 20 mM 
(NH4)2SO4), 2.5 mM MgCl2 [Thermo Fisher Scientific], 0.5 mM dNTP's [Thermo Fisher Scientific] (250 µM 
dTTP, 250 µM dATP, 250 µM dGTP, 250 µM dCTP), 0.15 mM of both primers (forward 
and reverse) [Frilabo], 0.3 µL Taq DNA polymerase [Thermo Fisher Scientific] (0.6 U) and 30 to 50 
ng of genomic DNA, making up to volume with bidestilled water [B. Braun]. In a 
thermocycler PCR reaction was performed according to the following conditions: an 
initial denaturation step at 95°C for 10 min, followed by 35 cycles of 95°C for 1 minute, 
annealing step at 55°C for 1 minute and a 1 minute extension step at 72°C. A final 
extension step was done at 72°C for 10 min.  
Fragments were analyzed for length variations on an ABI PRISMTM 310 Genetic 
Analyzer DNA sequencer (as previously described) and allele sizes were determined 
using the Gene Mapper® software. The results were independently scored by two 
observers and an additional round of analyses confirmed the results.  
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IV. RESULTS 
 
1. Identification of Lynch syndrome cases harboring 
constitutional MLH1 promoter methylation 
The methylation status of the MLH1 promoter was analyzed by methylation-
specific multiplex ligation-dependent probe amplification (MS-MLPA) in PBL samples of 
38 patients with clinical criteria for LS, with no germline MLH1 mutations and with no 
MLH1 immunoexpression on their tumors. In all cases, methylation in the MLH1 
promoter was studied in the five regions analyzed, including  C- and D-Deng promoter 
regions (figure 9), the most correlated with transcriptional regulation (Deng et al., 
2002).  
 
 
 
Constitutional methylation of the MLH1 promoter was detected in four (4/38; 
10.5%) patients (table 6). The mean age at diagnosis of these patients was 36 (range 
was 26-48 years). The clinical and molecular features of positive patients for 
constitutional methylation of the MLH1 promoter are presented in table 7. The 
methylation level detected in PBL at the C-Deng region (the region directly involved in 
MLH1 transcriptional activity) was on average of 28%, indicating that this alteration is 
present in mosaic. Figure 10 shows an electropherogram plot of a positive case for 
constitutional methylation in the MLH1 promoter studied by MS-MLPA. 
 We also studied MLH1 promoter methylation in samples representative of all 
embryonic layers, namely: tumor and normal colon mucosa (endoderm), buccal 
 
 
 
Figure 9 - Detailed methylation patterns of MLH1 promoter, assessed by MS-MLPA. The 
five regions of the CpG islands targeted by the selected probes are shown (adapted from 
Gausachs et al., 2012). Yellow rectangle highlight the most important regions. 
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mucosa (ectoderm) and muscle (mesoderm). MLH1 methylation levels reveled by MS-
MLPA analysis of these tissues does not differ significantly from those observed in PBL 
(mesoderm) (Table 6), demonstrating that this epigenetic alteration affects similarly the 
tissues from different embryonic origins.  
 We were able to study three relatives (parents and sister) of one of the probands 
with constitutional methylation of the MLH1 promoter (patient #27), and none of them 
present constitutional methylation of the MLH1 promoter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 10 - Electropherogram plot representing MS-MLPA in a PBL with constitutional 
methylation of the MLH1 promoter. The C- and D-Deng regions, the most important regions 
associated with the transcription of MLH1 gene, are highlighted with the red arrows. 
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Table 6 - MLH1 methylation levels (%) using MS-MLPA in samples from different germline origins in the four probands. 
 
% MLH1 Methylation 
 
 
NA, not available; PBL, peripheral blood lymphocytes. 
 
*Patient died during the study, so it was not possible to study buccal mucosa. 
Patient 
PBL             Tumor Normal Colon Mucosa Buccal Mucosa Muscle 
C Region 
(-246 nt) 
D Region 
(-13 nt) 
 
C Region  
(-246 nt) 
D Region 
(-13 nt) 
 
C Region  
(-246 nt) 
D Region 
(-13 nt) 
 
C Region  
(-246 nt) 
D Region 
(-13 nt) 
 
C Region  
(-246 nt) 
D Region 
(-13 nt) 
 
#3 
 
14.1 
 
 
43.3 
 
 
20.4 
 
 
62.9 
 
 
8.35 
 
 
27.7 
 
 
12.4 
 
 
44.5 
 
 
11.1 
 
 
32.3 
#10 18.3  49.9  11  32.2  9.1  
 
30.5 
 
 
 
NA* 
 
      NA*  NA*  NA* 
#27 32.6  51.4  13  38.6  14.4  35.4  13.8  40.5  12.2  39.5 
 
#38 
 
46.3 
 
 
52.3 
 
 
16.4 
 
 
40.2 
 
 
11.5 
 
 
36 
 
 
11.6 
 
 
36.4 
 
 
NA 
 
 
NA 
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Table 7 - Clinical and molecular features of patients with constitutional methylation of the MLH1 promoter. 
 
Age 
(years) 
Sex Proband 
Samples 
Studied by MS-
MLPA 
 
Promoter 
variants 
BRAF Familial history 
 
MLH1 
methylation in 
relatives 
#3 52 M 
 Metachronous 
CRC at age <50 
years 
PBL, CRC, normal 
colon mucosa, 
buccal mucosa and 
muscle 
 
ht  
c.-93G>A 
WT None NS 
#10a 60 F 
CRC at age 26 
years  
 
PBL, CRC and 
normal colon mucosa 
 
 
None WT 
First degree (maternal) relative with stomach 
cancer 
NS 
#27 36 M 
CRC at age <50 
years 
PBL, CRC, normal 
colon mucosa, 
buccal mucosa and 
muscle 
       
None WT 
Maternal great-grandmother with breast cancer, 
a paternal grandfather with prostate cancer, a 
paternal grandmother with colon cancer and  
father with bladder cancer 
Father*, mother* 
and sister* 
#38 49 M 
Synchronous CRC 
at age <50 years 
 
PBL, CRC, normal 
colon mucosa, 
buccal mucosa 
 
ht 
c.269C>G 
WT 
 
Father with liver and kidney cancers. Mother with 
uterine and endometrium cancers 
NS 
 
CRC, colorectal cancer; F, female; ht, heterozygous; IHC, immunohistochemistry; NS, not studied; M, male; PBL, peripheral blood lymphocytes; WT, 
wildtype.  
 
*Negative for MLH1 promoter methylation.                                       
a This patient died during the study. 
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2. Confirmation of correct MS-MLPA probe hybridization  
Sanger sequencing of the whole MLH1 promoter (from c.-1469 to intron 1) was 
performed in PBL samples from all cases, probands (n=38) and relatives (n=3) in order to 
find out if there were any variants which might inhibit the binding of the MS-MLPA probes. 
The results showed that none of the cases had DNA variants affecting the binding sites of 
the MS-MLPA probes or the HhaI restriction sites. Nonetheless, analysing the entire 
promoter region of the MLH1 gene, we found that one patient, who did not present 
constitutional methylation of MLH1, had the alteration c.-261G>A (rs587782685) 
described as a variant of unknown significance (VUS) in the ClinicalVar NCBI database 
(www.ncbi.nih.gov/clinvar). This change is outside to the probe hybridization site (-246 nt). 
Another heterozygous alteration, the c.-269C>G (rs35032294) (Zavodna et al., 2006), was 
found in patient #38 (table 8), being also outside to the probe hybridization site. Therefore, 
although these changes are located near the end of the probe hybridization site, this did 
not influence the hybridization efficiency because no copy number changes were found by 
MS-MLPA.  
Additionally, a common SNP, the c.-93G>A (rs180073439) relative to the translation 
start site of MLH1, was found in heterozygosity in sixteen cases (16/38; 42%), including 
patient #3 with constitutional methylation, and in homozygosity in one case (1/30; 2.6%). 
This common polymorphism is also outside the probe hybridization sites. No other 
variants were found in the MLH1 promoter region. 
 
3. Clinico-pathological features of patients with constitutional 
methylation of the MLH1 promoter 
Case #3 was a male who had two tumors of the descending colon, one at 38 and 
another at 45 years of age (metachronous tumors). The patient had no family history of 
cancer as it is shown in the family pedigree (figure 11 A). 
Case #10 was a female who was diagnosed with a moderately differentiated 
adenocarcinoma in the ascending colon at the age of 26 years. At 60 years of age, the 
patient was diagnosed with a stomach carcinoma. This patient presented scant family 
history of cancer, namely a maternal uncle affected with gastric cancer at age 70 years. 
The patient deceased at age 60 years during the course of this study (figure 11 B). 
Case #27 was a male who was diagnosed with an invasive adenocarcinoma in the 
rectum at the age of 33 years. This patient has family history of cancer, namely, a 
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maternal great-grandmother with breast cancer, a paternal grandfather with prostate 
cancer, a paternal grandmother with colon cancer, and the father with bladder cancer 
(figure 11 C). The father and the healthy mother and sister also participated in this study 
(figure 11 C). 
Case #38 was a male who was diagnosed with three different colon synchronous 
tumors in the ascending, transverse and descending colon at age of 48 years. The 
patient´s father was affected by kidney and liver cancer at the age of 60 years and the 
mother was affected by an endometrium cancer at the age 65 years (figure 11 D). 
None of the tumors of the four patients with constitutional methylation of the MLH1 
promoter presented the p.Val600Glu BRAF mutation. 
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Figure 11 - Family pedigrees of four patients positive for constitutional methylation of the 
MLH1 promoter.  Family history of the four patients with constitutional methylation (A) #3; B) #10; 
C) #27; D) #38) with age (in years) and health status. Black arrows indicate the probands. 
Abbreviations: met-, with no methylation of the MLH1 promoter; met+, with methylation of the 
MLH1 promoter. Circles, females; squares, males; semi filled, cancer affected. 
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4.  Quantification of the MLH1 transcript 
In order to assess global MLH1 transcript levels, we measured its relative 
expression levels by semiquantitative multiplex RT-PCR in PBL samples of patients with 
constitutional methylation (#3, #10, #27, #38) and controls. We amplified the MLH1 
transcript and an internal control, the beta-2-microglobulin (B2M). 
As shown by the electrophoretic profile of the multiplex RT-PCR products (figure 
12), in the cases positive for constitutional methylation we observed a decrease of MLH1 
RNA expression compared to controls.  
 
 
 
 
 
 
To confirm and measure the differences in the transcript levels observed in the 
electrophoresis of the multiplex RT-PCR products from patients with constitutional 
methylation and controls, we performed fragment analysis. The results obtained are 
shown in figure 13.   
The MLH1 transcript levels were calculated by comparing the relative peak areas of 
the MLH1 transcript to the relative peak areas of the beta-2-microglobulin (B2M).  
Controls presented an average of 99% of MLH1 transcript expression relatively to 
B2M. Considering our four cases with constitutional methylation, patient #3 presented a 
decrease of 38%; patient #10 a decrease of 37%; patient #27 a decrease of 46% and 
patient #38 a decrease of 38% of MLH1 transcript levels when compared to B2M (figure 
13). 
 
 
Figure 12 - Electrophoretic pattern of multiplex RT-PCR products. This was obtained for the 
four positive patients for constitutional methylation and five normal controls, where M is the 
molecular weight marker (100bp) and B2M is beta-2-microglobulin. 
Controls 
#3 #10 #27 #38 
B2M 
200 bp 
300 bp 
M 
MLH1 
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5. MLH1 allelic expression  
Data available from the MLH1 germline mutation screening showed that two of the 
probands positive for constitutional methylation of the MLH1 promoter (patient #10 and 
#27) were heterozygous for the coding polymorphism c.655A>G, p.Ile219Val (rs1799977) 
in exon 8. In order to evaluate if the MLH1 promoter methylation were monoallelic, the 
cDNA of this patients was sequenced in PBL samples. In both cases, both alleles were 
present, but one of them appeared to be less expressed (figure 14 A). This difference was 
more evident when compared with controls (figure 14 B). 
 
 
 
 
  
       
Figure 14 - Electropherogram of sequencing analysis demonstrating the allelic expression 
of the SNP rs1799977 in exon 8 of MLH1 in cDNA samples. Patient #10 (A), Control (B) (both 
reverse).  
 
A 
B2M 
MLH1 
B2M MLH1 
B 
Figure 13 - Electropherogram of fragment analysis of the multiplex RT-PCR products. The relative 
peak areas of a positive case for constitutional methylation (A) and control (B) are shown. In the case 
with constitutional methylation, a decreased MLH1 expression relatively to the internal control was 
verified. 
B 
c.655A>G  
A 
c.655A>G  
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In order to confirm these results, we performed on gDNA and cDNA SNuPe 
analysis specific for the rs1799977 (c.655A>G), in the two constitutional methylation-
positive patients heterozygous for this polymorphism (cases #10 and #27) and in controls 
(also heterozygous).  
In the gDNA, no significant differences were obtained in the A/G allele relative 
areas (case #10: 86%; case #27: 86%; and controls: 88%, figures 15 and 16). In the 
cDNA, we observed that both alleles were expressed in the two probands, but in both 
cases the A allele showed a signal reduction not observed in the controls (figure 15). 
These results suggest a decrease in the expression of the A allele. We observed a 45% 
decrease of the A allele relative to the G allele in patient #10 (figure 15) and a 27% 
decrease in patient #27 (figure 16). In controls, the difference between the two alleles was 
2%. Moreover, the normalized ratios between cDNA and gDNA revealed a 53% and a 
32% decrease of A allele in case #10 and in case #27, respectively. In controls, the 
normalized ratio obtained was of <0.1%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MLH1 rs1799977, case #10 
Figure 15 - SNuPE analysis at MLH1 rs1799977 (c.655A>G) in gDNA (upper panels) and in 
cDNA (bottom panels) of an heterozygous patient, case #10 with constitutional methylation 
(left panels) and of a control (right panels). Partial transcriptional silencing of the A allele in the 
cDNA of the patient was observed. 
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A allele 
Figure 16 - SNuPE analysis at MLH1 rs1799977 (c.655A>G) in gDNA (upper panels) and in 
cDNA (bottom panels) of an heterozygous patient, case #27 with constitutional methylation 
(left panels) and of a control (right panels). Partial transcriptional silencing of the A allele in the 
cDNA of the patient was observed. 
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6. Microsatellite instability analysis  
 Microsatellite instability analysis was performed by fragment analysis (using the 
Bethesda panel) in all four patients positive for constitutional methylation. This analysis 
was performed in tumors and normal mucosa samples. All cases with constitutional 
methylation of the MLH1 promoter have shown MSI-H in their tumors. In more detail, 
cases #3, #10, and #27 had instability in 50% of the markers and case #38 showed 
instability in 100% of the markers (figure 16). 
 
 
Figure 17 - Fragment analysis showing microsatellite sequences of mononucleotide 
BAT26 in cases #3 (A), #10 (B), #27 (C), and #38 (D). This analysis was performed in tumors 
(blue) and normal colon mucosa (green) samples in order to compare both tissues. 
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V. DISCUSSION 
 
It is nowadays recognized that epimutations are often associated with inactivation of 
tumor-suppressor genes and activation of proto-oncogenes that play a central role in 
carcinogenesis (Herceg and Vaissière, 2011; Sharma et al., 2009). The epigenetic 
disruption can predispose to mutation events, emphasizing the importance of both genetic 
and epigenetic alterations in carcinogenesis (Dobrovic and Kristensen, 2009; Sharma et 
al., 2009). 
Lynch syndrome is caused by germline mutations in the MMR genes, mainly 
affecting MLH1 and MSH2. Besides genetic mutations, constitutional epigenetic silencing 
of the MMR genes MLH1 and MSH2 has been recently reported as another possible 
cause of LS (Crépin et al., 2012; Hitchins, 2013; Lynch et al., 2015; Sehgal et al., 2014). 
Recently, constitutional MLH1 methylation has been identified in a subset of cases with  
clinical criteria for LS and with loss of the MLH1 protein in the tumor, but without identified 
germline mutations in the MMR genes (Crépin et al., 2012; Hitchins, 2013; Hitchins and 
Ward, 2009; Morak et al., 2008; Pineda et al., 2012; Ward et al., 2012). Constitutional 
methylation of MLH1 is characterized by dense CpG island promoter methylation of a 
single allele throughout the somatic tissues, accompanied by transcriptional inactivation of 
the affected allele (Coppedè et al., 2014; Hitchins and Ward, 2009).  
 
1. MLH1 constitutional methylation  
In this study we aimed to investigate the prevalence of MLH1 constitutional 
methylation in patients who met clinical criteria for LS, as well as to deduce the pattern of 
constitutional methylation inheritance. For this purpose we screened 38 probands from 
families that fulfilled clinical criteria for LS, without germline mutations in MLH1 and 
presenting loss of MLH1 protein expression by IHC. We identified four patients with 
constitutional methylation of MLH1. The frequency of constitutional MLH1 methylation was 
10.5% (4/38), indicating that MLH1 methylation may account for a non-negligible 
proportion of LS. To our knowledge  and to date, there are at least 55 index cases without 
a conventional pathogenic germline MMR mutation that are carriers of constitutional 
MLH1 methylation (Castillejo et al., 2015; Hitchins, 2013). Here, we report four additional 
patients presenting constitutional MLH1 methylation. 
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In accordance with previous reports, on the clinical and pathological characteristics 
of the patients with constitutional MLH1 methylation, two of the four cases identified in this 
study had developed multiple LS tumors at an early age (Castillejo et al., 2015; Hitchins et 
al., 2007; Hitchins and Ward, 2009; Hitchins, 2013; Pineda et al., 2012; Ward et al., 2012), 
one having metachronous (case #3) and the other synchronous tumors (case #38). 
Regarding family history, 3/4 of the patients with constitutional methylation presented 
relatives with LS-associated cancers, but their ages at diagnosis are compatible with 
sporadic origins.  The fourth patient with constitutional MLH1 methylation did not present 
family history of cancer, which is quite common in this pathogenic mechanism (Castillejo 
et al., 2015; Crépin et al., 2012; Hitchins et al., 2007; Hitchins and Ward, 2009; Hitchins, 
2013; Ward et al., 2012). 
On all cases, methylation of the MLH1 promoter was studied in the five regions 
analysed, including the C- and D-Deng regions, being the C-Deng region the most directly 
correlated with transcriptional silencing and resulting loss of MLH1 protein expression 
(Deng et al., 2002). The methylation level detected in PBL at the C-Deng region was an 
average of 28% (table 6), indicating that this alteration is present in mosaic (the affected 
allele is not methylated in all cells), as described in other studies (Castillejo et al., 2015; 
Crépin et al., 2012; Pineda et al., 2012; Sloane et al., 2015). In these patients, methylation 
of the MLH1 gene was also detected in other tissues, like colorectal tumors and normal 
colon mucosa (endoderm), oral mucosa (ectoderm) and muscle (mesoderm), representing 
the three germ layers, and with methylation frequencies that are not significantly different 
from that found in PBL (mesoderm). The normal developmental process of epigenetic 
reprogramming in mammals has two major waves of reprogramming reset the epigenome. 
The first wave, the demethylation, occurs following fertilization in the early embryo and the 
second, de novo methylation, takes place in primordial germ cells (Fleming et al., 2008). 
Thus, since the methylation is present in equivalent levels in tissues derived from the 
three germ layers, we can infer that in these cases the methylation of MLH1 gene 
occurred early during embryogenesis, as previously reported in other studies (Hitchins, 
2013; Ward et al., 2012). In fact, we were able to study three relatives of patient #27 (a 
man with early onset CRC who showed methylation of the MLH1 promoter of around 30% 
in PBL samples), namely the parents and the sister, and none of them presented 
constitutional MLH1 methylation, suggesting that in this patient MLH1 methylation arose 
de novo, similarly to most cases reported to date (Hitchins and Ward, 2009; Hitchins, 
2013).  
The pattern of transmission of the different forms of epimutations in the MLH1 gene 
depends on its origin, and may be divided into two categories. First, the primary 
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epimutations usually arise spontaneously de novo and are reversible (but may 
occasionally be transmitted to the next generation), not following a Mendelian pattern of 
transmission (Hitchins, 2013). On the other hand, secondary epimutations occur as the 
result of a genetic mutation in cis, and therefore may follow the classic pattern of 
autosomal dominant transmission (Castillejo et al., 2015; Hitchins, 2013). A dominantly 
transmitted constitutional MLH1 methylation has been linked to a MLH1 haplotype bearing 
two single-nucleotide variants: c.-27C>A and c.85G>T (p.Ala29Ser) (Kwok et al., 2014; 
Pineda et al., 2012). Studies of the c.-27C>A variant offer the most compelling evidence 
that MLH1 promoter variants can directly affect the regulation of MLH1 (Hitchins, et al., 
2011; Kwok, et al., 2014; Ward, et al., 2012) and has been associated with reduced 
transcriptional activity and the dominant inheritance of a mosaic constitutional MLH1 
methylation (Hitchins, et al., 2011; Hesson et al., 2014). In our series this variant was not 
found and, we excluded the hypothesis of secondary epimutations as the mechanism for 
the cases we here present. Sanger sequencing of the whole MLH1 promoter (from c.-
1469 to intron 1) was performed in PBL from all probands (n=38) and in the available 
relatives (n=3). No variants affecting the binding of MS-MLPA probes or HhaI restriction 
sites were found, making it more likely that the patients here reported have primary 
constitutional methylation. The fact that in our cases the methylation was present in 
mosaic makes it more likely to be a primary epimutation. However, we cannot exclude the 
remote possibility that there is a mutation in cis (outside the regions studied), causing a 
secondary methylation. For a more definitive classification of these epimutations, it would 
be necessary to perform additional studies, including offspring haplotypes studies. To 
know the precise mechanism would allow better risk predictions for the relatives 
concerning the development of neoplasms associated with LS and more tailored 
screening and prophylactic measures. 
 
2. MLH1 expression pattern  
We have also proposed to verify if MLH1 RNA expression was altered in PBL 
samples, when compared to selected controls and using B2M as internal control. We 
concluded that there was significant loss of expression of MLH1 in the four positive cases 
with constitutional methylation of the MLH1 gene when compared to controls. Our results 
are in agreement with other studies showing that constitutional methylation causes a 
transcriptional silencing of MLH1 gene and indicating that these events are correlated 
(Pineda et al., 2012; Ward et al., 2012).  
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Two of the probands positive for constitutional methylation of the MLH1 promoter 
(patient #10 and #27) were heterozygous for the coding polymorphism c.655A>G, 
p.Ile219Val (rs1799977) within MLH1 exon 8. We took advantage of this heterozygous 
polymorphism to determine the effect of the methylation in the MLH1 transcriptional 
activity. In order to evaluate if the MLH1 promoter methylation were monoallelic, we 
sequenced the cDNA of these patients. In both cases, both alleles were present, but one 
of them was less expressed when compared with controls. These results we confirmed by 
SNuPE analysis performed on gDNA and cDNA. Allele-specific expression values 
obtained revealed a decrease in the A allele of 45% and of 27% (relatively to the controls) 
in cases #10 and #27, respectively. Therefore, it is assumed that the allele methylated is 
the A allele showing lower expression. In summary, the RNA studies demonstrated a 
decrease of the MLH1 gene expression in cases with constitutional methylation, indicating 
that these events are correlated. Recent studies have also shown that MLH1 methylation 
can present itself as a constitutional alteration that results in the silencing of the affected 
allele (Gazzoli et al., 2002; Goel et al., 2011; Hitchins et al., 2005; Morak et al., 2008; 
Mrkonjic et al., 2010; Sloane et al., 2015).  
 
3. Molecular characterization of the tumors 
In patients with LS, the somatic inactivation, or “second hit”, of the wild-type allele 
of the affected MMR gene leads to the abnormal function of the MMR gene. In turn, this 
leads to the accumulation of errors during DNA replication, especially in repetitive 
sequences known as microsatellites (Boland and Goel, 2010). Consequently, tumors from 
patients with LS characteristically demonstrate MMR deficiency, defined as the presence 
of microsatellite instability (MSI) and/or the loss of MMR protein expression, which are the 
hallmarks of this disorder (Cicek et al., 2011; Kawakami et al., 2015). This feature is 
present in more than 90% of LS-associated colorectal tumors, in general and also in those 
associated with somatic or constitutional epigenetic silencing of the MLH1 gene. Our 
results are in agreement with all of the published data, since all four tumors analyzed were 
MSI-H and present loss of expression of MLH1 both at the mRNA and protein level 
(Bouzourene et al., 2010; Cunningham et al., 2010; Deng et al., 2002; Domingo et al., 
2004).  
The BRAF V600E mutation has been detected predominantly in sporadic CRC. 
Consequently, the presence of a BRAF mutation is usually, evidence against the  
presence of LS (Giardiello et al., 2014). The evidence gathered so far strongly 
indicates that the presence of a BRAF mutation may exclude the occurrence of MLH1 
    
89 | The role of MLH1 constitutional methylation in Lynch syndrome    
 
constitutional methylation (Pérez-Carbonell et al., 2010). The p.Val600Glu BRAF mutation 
was absent in the tumors of the all four carriers of constitutional MLH1 methylation here 
reported, as it is the case for the majority of the reported cases in the literature (Crépin et 
al., 2012; Goel et al., 2011; Pineda et al., 2010). However, van Roon et al. (2010),  
Parsons et al. (2012), and Crépin et al. (2012) have reported LS cases with the 
p.Val600Glu BRAF mutation, showing that it is possible the co-existence of BRAF 
mutation with MLH1 constitutional methylation (van Roon et al., 2010; Crépin et al., 2012; 
Parsons et al., 2012), contrarily to what happens in LS due to germline mutations.  
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VI.  CONCLUSION 
 
It is nowadays recognized that analysis of DNA methylation patterns offers an 
alternative strategy for the study of inactivation of tumor suppressor genes, when patients 
present loss of MLH1 protein expression and have no MLH1 pathogenic germline 
mutation. After completion of this study we conclude: 
 
 Constitutional MLH1 promoter methylation is present in about 10.5% of the 
patients without germline mutations and who present loss of protein MLH1 
expression in their tumors; 
 Constitutional methylation is present usually in mosaicism in tissues derived from 
all the germ layers, indicating that this phenomenon occurs in the early embryo;  
 Constitutional methylation is monoallelic and is associated with a significant 
decrease in MLH1 expression when compared with controls, indicating that these 
events are correlated;  
 Patients with constitutional methylation exhibit MSI-H and do not (or only rarely) 
present the p.Val600Glu BRAF mutation; 
 The fact that mosaic constitutional methylation was observed in all cases, together 
with its absence in the parents of the patient from whom relatives could be 
evaluated, makes it likely that the most common mechanism of constitutional 
methylation is primary epimutation.  
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VII.  FUTURE PERSPECTIVES 
 
This study may benefit from further analysis to support our conclusions and to allow 
a more specific evaluation of the clinical implications for the relatives of the patients with 
constitutional MLH1 methylation. Thus, we plan:  
 
 To quantify the methylation of the MLH1 gene by another technique, for 
example by pyrosequencing, in order to be able to confirm the results 
obtained by the MS-MLPA technique; 
 To analyze all available clinical data of each patient with constitutional 
methylation and their relatives; 
 To construct haplotypes in order to comprehend the transmission pattern in 
each family and the origin of methylation; 
 To increase our series in order to identify more index cases showing this 
epigenetic mechanism of LS. 
 
 
  
 
 
 
. 
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